Boehringer Ingelheim will apply Xencor's proprietary XmAb technology platform, including proprietary Fc domains, to maximize the efficacy of its antibody drug candidates against selected targets of interest.
Xencor's XmAb Fc domains are designed to enhance the therapeutic properties of antibodies including sustained half-life, increased structural stability and greater potency.
Under the terms of the agreement, Xencor will receive an upfront payment, and is eligible to receive additional license fees, milestones and a royalty payment on any products commercialized by Boehringer Ingelheim that incorporate the technology. Specific financial terms were not disclosed.